Form 4: Director Jonathan Mazelsky Receives RSU Grant at Dentsply

Director Jonathan Jay Mazelsky was granted 22,822 restricted stock units by Dentsply Sirona Inc. on June 3, 2026.

Summary

• Director Jonathan Jay Mazelsky acquired 22,822 Restricted Stock Units (RSUs) of Dentsply Sirona Inc. (XRAY).
• The transaction occurred on June 3, 2026, at a price of $0 per share as part of an equity grant.
• Following this transaction, the director's total beneficial ownership increased to 51,668.534 shares of common stock.
• The RSUs are scheduled to vest in full one year from the date of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standard equity compensation structure for board members.

Negatives

• None identified in this filing.

Risks

• Market volatility affecting the future value of the granted equity.
• Potential dilution impact, though minimal given the scale of the grant.

Future Outlook

The RSUs will vest in full on June 3, 2027, subject to the director's continued service.

Industry Context

StockSavvy.ai notes that equity grants to board members are a standard corporate governance practice in the medical technology sector to ensure long-term alignment with shareholder value creation.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with compensation practices at peer companies like Align Technology and Envista Holdings.
• Vesting periods of one year for director equity are standard within the S&P 500 and mid-cap healthcare indices.

Stakeholder Impact

• Shareholders benefit from increased director 'skin in the game'.

Next Steps

• Vesting of the 22,822 RSUs on June 3, 2027.

Key Dates

Keywords

Dentsply Sirona, XRAY, Form 4, Insider Trading, Restricted Stock Units, Director Compensation